Experimental drug shows efficacy in lowering glucose levels

02/26/2012 | Bloomberg

A study published in The Lancet showed 48% of type 2 diabetes patients who took Takeda Pharmaceuticals' TAK-875 for 12 weeks achieved blood glucose levels below a predetermined level, compared with 40% of those who received glimepiride. Researchers also found that 2% of patients who took TAK-875 developed hypoglycemia, compared with 19% in the glimepiride group.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN